Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Chronic Migraine Patients: COMPEL Analysis by Treatment Cycle

被引：0
|
作者：
Brin, Mitchell F. [1 ,2 ]
Winner, Paul [3 ]
Blumenfeld, Andrew M. [4 ]
Eross, Eric J. [5 ]
Orejudos, Amelia [1 ]
Adams, Aubrey Manack [1 ]
机构：
[1] Allergan Plc, Irvine, CA USA
[2] Univ Calif Irvine, Irvine, CA USA
[3] Premiere Res Inst Palm Beach Neurol, Palm Beach Headache Ctr, W Palm Beach, FL USA
[4] Headache Ctr Southern Calif, Neurol Ctr, Carslbad, CA USA
[5] CORE Inst, Scottsdale, AZ USA
来源：
NEUROLOGY | 2018年 / 90卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P4.123
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Long-term treatment of chronic migraine with OnabotulinumtoxinA: efficacy, quality of life and tolerability in a real-life setting
    Kollewe, Katja
    Escher, Claus M.
    Wulff, Dirk U.
    Fathi, Davood
    Paracka, Lejla
    Mohammadi, Bahram
    Karst, Matthias
    Dressler, Dirk
    JOURNAL OF NEURAL TRANSMISSION, 2016, 123 (05) : 533 - 540
  • [22] Efficacy and Safety of OnabotulinumtoxinA in an Open-Label Study for the Prophylactic Treatment of Chronic Migraine in Adult Patients: COMPEL
    Blumenfeld, Andrew
    Stark, Richard
    Adams, Aubrey Manack
    Orejudos, Amelia
    Aurora, Sheena
    NEUROLOGY, 2017, 88
  • [23] Efficacy and Safety of OnabotulinumtoxinA in an Open-Label Study for the Prophylactic Treatment of Chronic Migraine in Adult Patients: COMPEL
    Blumenfeld, Andrew
    Stark, Richard
    Adams, Aubrey Manack
    Orejudos, Amelia
    Aurora, Sheena
    NEUROLOGY, 2017, 88
  • [24] Rationale for Study and Design of COMPEL: An Open-Label, Multicenter Study of the Long-Term Efficacy, Safety, and Tolerability of OnabotulinumtoxinA for Headache Prophylaxis in Adults with Chronic Migraine
    Blumenfeld, A. M.
    Aurora, S. K.
    Laranjo, K.
    Varon, S. F.
    Papapetropoulos, S.
    HEADACHE, 2012, 52 (05): : 881 - 881
  • [25] OnabotulinumtoxinA: long term treatment for chronic migraine with medication overuse
    Guerzoni, Simona
    Cainazzo, Maria Michela
    Pini, Luigi Alberto
    JOURNAL OF HEADACHE AND PAIN, 2015, 16
  • [26] Efficacy and safety of onabotulinumtoxinA for the prophylaxis of headaches in adult chronic migraine patients: an interim analysis of the prospective, long-term, multicenter, open-label study, COMPEL
    Blumenfeld, A.
    Stark, R.
    Reppine, A.
    Halstead, M.
    Holdbrook, F.
    Adams, A. Manack
    Aurora, S.
    JOURNAL OF PAIN, 2015, 16 (04): : S92 - S92
  • [27] Unmet clinical needs in chronic migraine: Rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine
    Andrew M. Blumenfeld
    Sheena K. Aurora
    Karen Laranjo
    Spyros Papapetropoulos
    BMC Neurology, 15
  • [28] Unmet clinical needs in chronic migraine: Rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine
    Blumenfeld, Andrew M.
    Aurora, Sheena K.
    Laranjo, Karen
    Papapetropoulos, Spyros
    BMC NEUROLOGY, 2015, 15
  • [29] Long-term experience with onabotulinumtoxina in the treatment of chronic migraine: lessons after one year
    Pascual, J.
    Ramon, C.
    Larrosa, D.
    Riesco, N.
    Alvarez, R.
    Cernuda-Morollon, E.
    CEPHALALGIA, 2015, 35 : 54 - 54
  • [30] OnabotulinumtoxinA for Chronic Migraine: Safety and Tolerability of the Effective Treatment Paradigm in the PREEMPT Clinical Program
    Aurora, S. K.
    Dodick, D. W.
    Blumenfeld, A.
    DeGryse, R. E.
    Turkel, C. C.
    HEADACHE, 2010, 50 : S14 - S15
12345